Bridget Kramer
YOU?
Author Swipe
View article: Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial
Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial Open
Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on H…
View article: Unique transcriptomic profile of peripheral blood monocytes in rheumatoid arthritis-associated interstitial lung disease
Unique transcriptomic profile of peripheral blood monocytes in rheumatoid arthritis-associated interstitial lung disease Open
Objectives Though interstitial lung disease (ILD) contributes to excess morbidity and mortality in rheumatoid arthritis (RA), RA-ILD pathogenesis remains incompletely defined. As intermediate, non-classical and suppressed CD14+ monocytes a…
View article: Comparison of Gout Flares With the Initiation of Treat‐to‐Target Allopurinol and Febuxostat: A Post‐Hoc Analysis of a Randomized Multicenter Trial
Comparison of Gout Flares With the Initiation of Treat‐to‐Target Allopurinol and Febuxostat: A Post‐Hoc Analysis of a Randomized Multicenter Trial Open
Objective Initiating urate‐lowering therapy (ULT) in gout can precipitate arthritis flares. There have been limited comparisons of flare risk during the initiation and escalation of allopurinol and febuxostat, administered as a treat‐to‐ta…
View article: Determinants of Achieving Serum Urate Goal with <scp>Treat‐to‐Target Urate‐Lowering</scp> Therapy in Gout
Determinants of Achieving Serum Urate Goal with <span>Treat‐to‐Target Urate‐Lowering</span> Therapy in Gout Open
Objective Using trial data comparing treat‐to‐target allopurinol and febuxostat in gout, we examined participant characteristics associated with serum urate (SU) goal achievement. Methods Participants with gout and SU ≥6.8 mg/dL were rando…